UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

Journal of clinical oncology, 2013-06, Vol.31 (17), p.2128-2135

2013

Volltextzugriff (PDF)

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

Journal of clinical oncology, 2012-09, Vol.30 (26), p.3234-3241

2012

Volltextzugriff (PDF)

Comparison of younger and older breast cancer survivors and age‐matched controls on specific and overall quality of life domains

Cancer, 2014-08, Vol.120 (15), p.2237-2246

2014

Volltextzugriff (PDF)

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations

Clinical cancer research, 2018-07, Vol.24 (13), p.3163-3175

2018

Volltextzugriff (PDF)

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

Journal of clinical oncology, 2008-10, Vol.26 (28), p.4672-4678

2008

Volltextzugriff (PDF)

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Journal of clinical oncology, 2008-04, Vol.26 (11), p.1810-1816

2008

Volltextzugriff (PDF)

Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199

Clinical cancer research, 2015-11, Vol.21 (22), p.5082-5091

2015

Volltextzugriff (PDF)

A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer

Breast cancer research : BCR, 2018-08, Vol.20 (1), p.82-82, Article 82

2018

Volltextzugriff (PDF)

Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer

Journal of clinical oncology, 2005-02, Vol.23 (4), p.792-799

2005

Volltextzugriff (PDF)

Targeting progesterone signaling prevents metastatic ovarian cancer

Proceedings of the National Academy of Sciences - PNAS, 2020-12, Vol.117 (50), p.31993-32004

2020

Volltextzugriff (PDF)

Stromal heterogeneity may explain increased incidence of metaplastic breast cancer in women of African descent

Nature communications, 2023-09, Vol.14 (1), p.5683-22, Article 5683

2023

Volltextzugriff (PDF)

Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers

Breast cancer research : BCR, 2019-08, Vol.21 (1), p.87-87, Article 87

2019

Volltextzugriff (PDF)

Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy

NPJ breast cancer, 2017-07, Vol.3 (1), p.24-6, Article 24

2017

Volltextzugriff (PDF)

ADAM8 is expressed widely in breast cancer and predicts poor outcome in hormone receptor positive, HER-2 negative patients

Cancer cell international, 2023-08, Vol.23 (1), p.165-165, Article 165

2023

Volltextzugriff (PDF)

The Role of Vascular Endothelial Growth Factor Genetic Variability in Cancer

Clinical cancer research, 2009-09, Vol.15 (17), p.5297-5302

2009

Volltextzugriff (PDF)

Clinical-Translational Approaches to the Nm23-H1 Metastasis Suppressor

Clinical cancer research, 2008-08, Vol.14 (16), p.5006-5012

2008

Volltextzugriff (PDF)

Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer

Clinical cancer research, 2011-01, Vol.17 (2), p.372-381

2011

Volltextzugriff (PDF)

A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer

Clinical cancer research, 2005-05, Vol.11 (9), p.3369-3376

2005

Volltextzugriff (PDF)

A Personalized, Dynamic Physical Activity Intervention Is Feasible and Improves Energetic Capacity, Energy Expenditure, and Quality of Life in Breast Cancer Survivors

Frontiers in oncology, 2021-04, Vol.11, p.626180-626180

2021

Volltextzugriff (PDF)

Questioning Our APHINITY for More

The New England journal of medicine, 2017-07, Vol.377 (2), p.186-187

Miller, Kathy D

2017

Volltextzugriff (PDF)

Redefining the Target: Chemotherapeutics as Antiangiogenics

Journal of clinical oncology, 2001-02, Vol.19 (4), p.1195-1206

2001

Volltextzugriff (PDF)

Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer

NPJ breast cancer, 2022-02, Vol.8 (1), p.16-16, Article 16

2022

Volltextzugriff (PDF)

Inflammatory breast cancer appearance at presentation is associated with overall survival

Cancer medicine (Malden, MA), 2021-09, Vol.10 (18), p.6261-6272

2021

Volltextzugriff (PDF)

Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening

JAMA : the journal of the American Medical Association, 2020-02, Vol.323 (8), p.746

2020

Volltextzugriff (PDF)

1 – 25 von 350

Suche als RSS-Feed

Aktive Filter

KollektionEZB Electronic Journals Library

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(343)
Mit Volltextzugriff
(306)

Publikationsform

Artikel
(349)
magazinearticle
(1)

Sprache

Englisch
(350)
Japanisch
(60)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

Comparison of younger and older breast cancer survivors and age‐matched controls on specific and overall quality of life domains

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199

A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer

Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer

Targeting progesterone signaling prevents metastatic ovarian cancer

Stromal heterogeneity may explain increased incidence of metaplastic breast cancer in women of African descent

Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial)

Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers

Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy

ADAM8 is expressed widely in breast cancer and predicts poor outcome in hormone receptor positive, HER-2 negative patients

The Role of Vascular Endothelial Growth Factor Genetic Variability in Cancer

Clinical-Translational Approaches to the Nm23-H1 Metastasis Suppressor

Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer

A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer

A Personalized, Dynamic Physical Activity Intervention Is Feasible and Improves Energetic Capacity, Energy Expenditure, and Quality of Life in Breast Cancer Survivors

Questioning Our APHINITY for More

Redefining the Target: Chemotherapeutics as Antiangiogenics

Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer

Inflammatory breast cancer appearance at presentation is associated with overall survival

Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening

Aktive Filter

Suchergebnisse filtern